Roth Capital Has Negative Estimate for CYCC FY2027 Earnings

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Investment analysts at Roth Capital reduced their FY2027 earnings estimates for shares of Cyclacel Pharmaceuticals in a note issued to investors on Wednesday, October 23rd. Roth Capital analyst J. Aschoff now forecasts that the biotechnology company will earn $3.32 per share for the year, down from their prior forecast of $4.26. Roth Capital currently has a “Hold” rating on the stock. The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($2.29) per share. Roth Capital also issued estimates for Cyclacel Pharmaceuticals’ FY2028 earnings at $5.31 EPS.

Separately, StockNews.com started coverage on shares of Cyclacel Pharmaceuticals in a research note on Tuesday, October 22nd. They issued a “sell” rating for the company.

Cyclacel Pharmaceuticals Trading Down 15.9 %

NASDAQ CYCC opened at $0.70 on Monday. The business has a fifty day simple moving average of $1.03 and a 200 day simple moving average of $1.54. Cyclacel Pharmaceuticals has a 12 month low of $0.67 and a 12 month high of $10.12. The firm has a market capitalization of $1.51 million, a P/E ratio of -0.04 and a beta of 0.51.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 21,963.75%. During the same period in the prior year, the firm earned ($6.60) earnings per share.

Hedge Funds Weigh In On Cyclacel Pharmaceuticals

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned 9.18% of Cyclacel Pharmaceuticals at the end of the most recent quarter. 23.58% of the stock is currently owned by institutional investors.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.